A Phase 3 interventional study of Ibuprofen 600 mg Immediate Release/Extended Release Caplet in Pain, sponsored by Pfizer. Terminated at 27 sites in United States. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-24.
Sponsored by Pfizer · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies testing ibuprofen in Pain — 6 open to participants now, 6 under way, none of them phase 3. Ibuprofen · Pain.
Among the 86 studies testing ibuprofen in Pain, this one is the 2nd largest by enrollment, is one of 5 that started in 2018, is one of 22 in phase 3, and was the 61st registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →6 of the 86 studies testing ibuprofen in Pain are open now, in 4 countries. Recruiting first, the newest first:
Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi · Sites in Pakistan
Ages 18–60
October University for Modern Sciences and Arts · Sites in Egypt
Ages 6–12
Armed Forces Institute of Dentistry, Pakistan · Sites in Pakistan
Ages 18–50 · Healthy volunteers
Ankara City Hospital Bilkent · Sites in Turkey
Ages 18–80
Benaroya Research Institute · Sites in United States
Ages 18+ · Men only · Healthy volunteers
By country, each count listing its studies:
Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 12 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 10 · Phase 3 22 · Phase 4 30
First in 1998; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 613 is above the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 100 across the 86 interventional studies. Of the 69 that completed or were terminated, 32 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 86 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
74 studies in Pain by Pfizer: none open now, none under way, none of them phase 3. Of 72 finished, 34 (47%) have results posted.
Among the 74 studies in Pain by Pfizer, this one is the 8th largest by enrollment of the 71 interventional ones that give a count, is the only one that started in 2018, is one of 28 in phase 3, and was the 73rd registered.
Pfizer’s Pain studies by the year they started, since 2001.
2 of the studies testing ibuprofen in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07512297University of GaziantepPain Control During ESWL Using Non-Opioid Analgesics | 2027-01-01 |
| NCT07275710Armed Forces Post Graduate Medical Institute (AFPGMI), RawalpindiRole of Alprazolam in Management of Post Endodontic Pain After Single Visit Root Canal Treatment. To Compare Mean Pain Score Between Two Group of Participants Undergoing Post Operative Pain Management After Single Visit Root Canal Treatment: NSAIDs Alone and a Combination of NSAIDs and Alprazolam. | 2027-01-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 86 studies testing ibuprofen in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 74 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This will be an open-label, multicenter, 30-day, unsupervised AUS among targeted (at-risk) adult and adolescent consumers designed to mimic an OTC-like environment. More specifically, "at-risk" consumers, as discussed with the FDA, will comprise elderly consumers (>65 years of age), consumers with an increased risk of gastrointestinal (GI) bleeding or cardiovascular (CV) adverse events, consumers who experience severe pain, low literacy subjects, and adolescents (12-17 years of age). The total number of subjects expected to enroll into the study is approximately 820. Sites will be pharmacies in diverse geographic locations around the US. Prospective adult subjects will be recruited via general population and targeted risk condition advertising (although participants will not be informed as to specific health conditions for which they are being recruited), while adolescents will be recruited using targeted, outbound pre-recruiting telephone calls. Subjects (or the parents/guardians of prospective adolescent subjects) responding to the advertisements or recruitment calls will be initially screened by telephone, and eligibility will subsequently be verified in-person at the pharmacy site.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:
Male or female 18 years of age or older, has history of using oral OTC analgesics at OTC dose levels, defined as taking at least 5 doses/month on average during the past 3 months, and qualifies for inclusion in at least one risk group category, including cardiovascular, gastrointestinal bleeding, history of severe pain (≥5 episodes in last month) or >65 years of age (see Groups 1 4 in Section 3.1).
OR Male or female 12-17 years of age and has history of using oral OTC analgesics at OTC dose levels, defined as taking at least 5 doses/month on average during the past 3 months.
Exclusion Criteria
Subjects with any of the following characteristics/conditions will not be included in the study:
Refuses to participate in required assessments (such as urine pregnancy, finger stick cholesterol or blood pressure tests, or unable or unwilling to comply with electronic diary procedures).
The following additional exclusion criteria will be applied for adolescent subjects only (12-17 years of age):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ibuprofen 600 mg Immediate Release/Extended Release Tablets
Drug: Ibuprofen 600 mg Immediate Release/Extended Release Caplet
Drug page: Ibuprofen
Ibuprofen 600 mg Immediate Release/Extended Release Tablet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.
Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Daily Dose of 1200 mg on 2 or More Calendar Days During the Use Period
Use period was defined as 30 days from purchase.
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Daily Dose of 1200 mg on 2 or More Calendar Days During the Use Period
Use period was defined as 30 days from purchase.
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Daily Dose of 1200 mg on 2 or More Calendar Days During the Use Period
Use period was defined as 30 days from purchase.
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Daily Dose of 1200 mg on 2 or More Calendar Days During the Use Period
Use period was defined as 30 days from purchase.
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During the Use Period
Use period was defined as 30 days from purchase.
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During the Use Period
Use period was defined as 30 days from purchase.
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During the Use Period
Use period was defined as 30 days from purchase.
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During the Use Period
Use period was defined as 30 days from purchase.
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During Use Period Due to Unintentional Misuse
Unintentional misuse: Participants who did not understand the dosing instructions on the package. Use period was defined as 30 days from purchase.
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During Use Period Due to Unintentional Misuse
Unintentional misuse: Participants who did not understand the dosing instructions on the package. Use period was defined as 30 days from purchase.
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During Use Period Due to Unintentional Misuse
Unintentional misuse: Participants who did not understand the dosing instructions on the package. Use period was defined as 30 days from purchase.
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During Use Period Due to Unintentional Misuse
Unintentional misuse: Participants who did not understand the dosing instructions on the package. Use period was defined as 30 days from purchase.
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Amount Per Dose of 600 mg on 1 or More Occasions
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Amount Per Dose of 600 mg on 1 or More Occasions
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Amount Per Dose of 600 mg on 1 or More Occasions
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Amount Per Dose of 600 mg on 1 or More Occasions
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Amount Per Dose of 600 mg on 2 or More Occasions
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Amount Per Dose of 600 mg on 2 or More Occasions
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Amount Per Dose of 600 mg on 2 or More Occasions
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Amount Per Dose of 600 mg on 2 or More Occasions
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Daily Dose of 1200 mg on 10 or More Calendar Days
Participants did not need to necessarily use the study medication for 10 consecutive days.
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Daily Dose of 1200 mg on 10 or More Calendar Days
Participants did not need to necessarily use the study medication for 10 consecutive days.
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Daily Dose of 1200 mg on 10 or More Calendar Days
Participants did not need to necessarily use the study medication for 10 consecutive days.
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Daily Dose of 1200 mg on 10 or More Calendar Days
Participants did not need to necessarily use the study medication for 10 consecutive days.
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Daily Dose of 1200 mg on 7 or More Calendar Days
Participants did not need to necessarily use the study medication for 7 consecutive days.
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Daily Dose of 1200 mg on 7 or More Calendar Days
Participants did not need to necessarily use the study medication for 7 consecutive days.
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Daily Dose of 1200 mg on 7 or More Calendar Days
Participants did not need to necessarily use the study medication for 7 consecutive days.
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Daily Dose of 1200 mg on 7 or More Calendar Days
Participants did not need to necessarily use the study medication for 7 consecutive days.
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 1 Who Took More Than 2 Doses on a Calendar Day
More than 2 doses on a calendar day means more than 2 dosing occasions on a calendar day.
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 2 Who Took More Than 2 Doses on a Calendar Day
More than 2 doses on a calendar day means more than 2 dosing occasions on a calendar day.
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 3 Who Took More Than 2 Doses on a Calendar Day
More than 2 doses on a calendar day means more than 2 dosing occasions on a calendar day.
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 4 Who Took More Than 2 Doses on a Calendar Day
More than 2 doses on a calendar day means more than 2 dosing occasions on a calendar day.
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 1 Who Re-dosed in Less Than (<)12 Hours, <10 Hours and <8 Hours on 1 or More Occasions
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 2 Who Re-dosed in Less Than (<)12 Hours, <10 Hours and <8 Hours on 1 or More Occasions
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 3 Who Re-dosed in Less Than (<)12 Hours, <10 Hours and <8 Hours on 1 or More Occasions
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 4 Who Re-dosed in Less Than (<)12 Hours, <10 Hours and <8 Hours on 1 or More Occasions
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 1 Who Used the Product on More Than 10 Consecutive Calendar Days
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 2 Who Used the Product on More Than 10 Consecutive Calendar Days
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 3 Who Used the Product on More Than 10 Consecutive Calendar Days
Time frame: From first purchase of study drug (Day 1) to Day 30
Percentage of Participants in Data Analysis Set 4 Who Used the Product on More Than 10 Consecutive Calendar Days
Time frame: From first purchase of study drug (Day 1) to Day 30
| Milestone | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Started | 608 | 5 |
| Safety set | 198 | 5 |
| Actual drug users | 179 | 5 |
| Completed | 143 | 4 |
| Not completed | 465 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lost to follow-up | 6 | 0 |
| Withdrew: Partial missing data | 44 | 1 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Other | 4 | 0 |
| Withdrew: Not returned to sign consent, download electronic diary application or to purchase study medication | 2 | 0 |
| Withdrew: Did not meet risk classification group criteria | 90 | 0 |
| Withdrew: Did not sign consent | 17 | 0 |
| Withdrew: Other eligibility criteria not met pre-consent | 22 | 0 |
| Withdrew: Not willing to purchase study medication | 142 | 0 |
| Withdrew: Did not qualify at re-screening and medical conditions | 133 | 0 |
Use period was defined as 30 days from purchase.
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Daily Dose of 1200 mg on 2 or More Calendar Days During the Use Period | 10.6 (6.1 to 15.1) | 0.0 (0.0 to 0.0) |
Use period was defined as 30 days from purchase.
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Daily Dose of 1200 mg on 2 or More Calendar Days During the Use Period | 7.8 (3.9 to 11.8) | 0.0 (0.0 to 0.0) |
Use period was defined as 30 days from purchase.
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Daily Dose of 1200 mg on 2 or More Calendar Days During the Use Period | 7.3 (3.5 to 11.1) | 0.0 (0.0 to 0.0) |
Use period was defined as 30 days from purchase.
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Daily Dose of 1200 mg on 2 or More Calendar Days During the Use Period | 2.8 (0.4 to 5.2) | 0.0 (0.0 to 0.0) |
Use period was defined as 30 days from purchase.
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During the Use Period | 22.9 (16.7 to 29.1) | 0.0 (0.0 to 0.0) |
Use period was defined as 30 days from purchase.
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During the Use Period | 16.2 (10.8 to 21.6) | 0.0 (0.0 to 0.0) |
Use period was defined as 30 days from purchase.
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During the Use Period | 14.0 (8.9 to 19.0) | 0.0 (0.0 to 0.0) |
Use period was defined as 30 days from purchase.
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During the Use Period | 6.1 (2.6 to 9.7) | 0.0 (0.0 to 0.0) |
Unintentional misuse: Participants who did not understand the dosing instructions on the package. Use period was defined as 30 days from purchase.
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During Use Period Due to Unintentional Misuse | 3.4 (0.7 to 6.0) | 0.0 (0.0 to 0.0) |
Unintentional misuse: Participants who did not understand the dosing instructions on the package. Use period was defined as 30 days from purchase.
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During Use Period Due to Unintentional Misuse | 2.2 (0.1 to 4.4) | 0.0 (0.0 to 0.0) |
Unintentional misuse: Participants who did not understand the dosing instructions on the package. Use period was defined as 30 days from purchase.
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During Use Period Due to Unintentional Misuse | 2.2 (0.1 to 4.4) | 0.0 (0.0 to 0.0) |
Unintentional misuse: Participants who did not understand the dosing instructions on the package. Use period was defined as 30 days from purchase.
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Daily Dose of 1200 mg on 1 or More Calendar Days During Use Period Due to Unintentional Misuse | 2.2 (0.1 to 4.4) | 0.0 (0.0 to 0.0) |
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Amount Per Dose of 600 mg on 1 or More Occasions | 30.7 (24.0 to 37.5) | 20.0 (0.0 to 55.1) |
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Amount Per Dose of 600 mg on 1 or More Occasions | 22.3 (16.2 to 28.4) | 20.0 (0.0 to 55.1) |
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Amount Per Dose of 600 mg on 1 or More Occasions | 19.0 (13.2 to 24.7) | 20.0 (0.0 to 55.1) |
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Amount Per Dose of 600 mg on 1 or More Occasions | 13.4 (8.4 to 18.4) | 0.0 (0.0 to 0.0) |
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Amount Per Dose of 600 mg on 2 or More Occasions | 17.9 (12.3 to 23.5) | 0.0 (0.0 to 0.0) |
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Amount Per Dose of 600 mg on 2 or More Occasions | 14.5 (9.4 to 19.7) | 0.0 (0.0 to 0.0) |
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Amount Per Dose of 600 mg on 2 or More Occasions | 13.4 (8.4 to 18.4) | 0.0 (0.0 to 0.0) |
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Amount Per Dose of 600 mg on 2 or More Occasions | 7.8 (3.9 to 11.8) | 0.0 (0.0 to 0.0) |
Participants did not need to necessarily use the study medication for 10 consecutive days.
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Daily Dose of 1200 mg on 10 or More Calendar Days | 1.1 (0.0 to 2.7) | 0.0 (0.0 to 0.0) |
Participants did not need to necessarily use the study medication for 10 consecutive days.
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Daily Dose of 1200 mg on 10 or More Calendar Days | 1.1 (0.0 to 2.7) | 0.0 (0.0 to 0.0) |
Participants did not need to necessarily use the study medication for 10 consecutive days.
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Daily Dose of 1200 mg on 10 or More Calendar Days | 1.1 (0.0 to 2.7) | 0.0 (0.0 to 0.0) |
Participants did not need to necessarily use the study medication for 10 consecutive days.
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Daily Dose of 1200 mg on 10 or More Calendar Days | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) |
Participants did not need to necessarily use the study medication for 7 consecutive days.
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 1 Exceeding the Maximum Daily Dose of 1200 mg on 7 or More Calendar Days | 1.1 (0.0 to 2.7) | 0.0 (0.0 to 0.0) |
Participants did not need to necessarily use the study medication for 7 consecutive days.
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 2 Exceeding the Maximum Daily Dose of 1200 mg on 7 or More Calendar Days | 1.1 (0.0 to 2.7) | 0.0 (0.0 to 0.0) |
Participants did not need to necessarily use the study medication for 7 consecutive days.
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 3 Exceeding the Maximum Daily Dose of 1200 mg on 7 or More Calendar Days | 1.1 (0.0 to 2.7) | 0.0 (0.0 to 0.0) |
Participants did not need to necessarily use the study medication for 7 consecutive days.
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 4 Exceeding the Maximum Daily Dose of 1200 mg on 7 or More Calendar Days | 0.6 (0.0 to 1.7) | 0.0 (0.0 to 0.0) |
More than 2 doses on a calendar day means more than 2 dosing occasions on a calendar day.
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 1 Who Took More Than 2 Doses on a Calendar Day | 11.7 (7.0 to 16.4) | 0.0 (0.0 to 0.0) |
More than 2 doses on a calendar day means more than 2 dosing occasions on a calendar day.
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 2 Who Took More Than 2 Doses on a Calendar Day | 7.8 (3.9 to 11.8) | 0.0 (0.0 to 0.0) |
More than 2 doses on a calendar day means more than 2 dosing occasions on a calendar day.
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 3 Who Took More Than 2 Doses on a Calendar Day | 7.3 (3.5 to 11.1) | 0.0 (0.0 to 0.0) |
More than 2 doses on a calendar day means more than 2 dosing occasions on a calendar day.
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 4 Who Took More Than 2 Doses on a Calendar Day | 2.8 (0.4 to 5.2) | 0.0 (0.0 to 0.0) |
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Re-dosed in <12 Hours | 47.5 (40.2 to 54.8) | 0.0 (0.0 to 0.0) |
| Re-dosed in <10 Hours | 36.3 (29.3 to 43.4) | 0.0 (0.0 to 0.0) |
| Re-dosed in <8 Hours | 29.1 (22.4 to 35.7) | 0.0 (0.0 to 0.0) |
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Re-dosed in <12 Hours | 43.0 (35.8 to 50.3) | 0.0 (0.0 to 0.0) |
| Re-dosed in <10 Hours | 28.5 (21.9 to 35.1) | 0.0 (0.0 to 0.0) |
| Re-dosed in <8 Hours | 19.6 (13.7 to 25.4) | 0.0 (0.0 to 0.0) |
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Re-dosed in <12 Hours | 42.5 (35.2 to 49.7) | 0.0 (0.0 to 0.0) |
| Re-dosed in <10 Hours | 26.8 (20.3 to 33.3) | 0.0 (0.0 to 0.0) |
| Re-dosed in <8 Hours | 17.3 (11.8 to 22.9) | 0.0 (0.0 to 0.0) |
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Re-dosed in <12 Hours | 39.7 (32.5 to 46.8) | 0.0 (0.0 to 0.0) |
| Re-dosed in <10 Hours | 18.4 (12.8 to 24.1) | 0.0 (0.0 to 0.0) |
| Re-dosed in <8 Hours | 12.3 (7.5 to 17.1) | 0.0 (0.0 to 0.0) |
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 1 Who Used the Product on More Than 10 Consecutive Calendar Days | 22.3 (16.2 to 28.4) | 0.0 (0.0 to 0.0) |
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 2 Who Used the Product on More Than 10 Consecutive Calendar Days | 22.9 (16.7 to 29.1) | 0.0 (0.0 to 0.0) |
| Percentage of participants | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Percentage of Participants in Data Analysis Set 3 Who Used the Product on More Than 10 Consecutive Calendar Days | 22.9 (16.7 to 29.1) | 0.0 (0.0 to 0.0) |
No measurements were reported for this outcome.
Collected over First purchase of study drug up to maximum of 45 days after last dose of study drug (for up to 75 days). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adult Compliance-Evaluable Population | 1/198 (0.5%) | 4/198 (2%) | 9/198 (4.5%) |
| Adolescent Users | 0/5 (0%) | 0/5 (0%) | 1/5 (20%) |
| Event | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| Victim of crimeSocial circumstances | 1/198 | 0/5 |
| Pancreatitis acuteGastrointestinal disorders | 1/198 | 0/5 |
| DepressionPsychiatric disorders | 1/198 | 0/5 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/198 | 0/5 |
| DeathGeneral disorders | 1/198 | 0/5 |
| Event | Adult Compliance-Evaluable Population | Adolescent Users |
|---|---|---|
| NauseaGastrointestinal disorders | 4/198 | 1/5 |
| NasopharyngitisInfections and infestations | 5/198 | 0/5 |
Safety set included all the participants who signed informed consent and purchased the product.
| Age, Categorical(Participants) | Adult Compliance-Evaluable Population | Adolescent Users | Total |
|---|---|---|---|
| <=18 years | 0 | 5 | 5 |
| Between 18 and 65 years | 150 | 0 | 150 |
| >=65 years | 48 | 0 | 48 |
| Sex: Female, Male(Participants) | Adult Compliance-Evaluable Population | Adolescent Users | Total |
|---|---|---|---|
| Female | 137 | 4 | 141 |
| Male | 61 | 1 | 62 |
| Ethnicity (NIH/OMB)(Participants) | Adult Compliance-Evaluable Population | Adolescent Users | Total |
|---|---|---|---|
| Hispanic or Latino | 10 | 1 | 11 |
| Not Hispanic or Latino | 188 | 4 | 192 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Dec 2018 to primary completion in Oct 2019, 10 months.
Results were first posted in Sep 2021, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibuprofen